Background Immunotherapy has recently emerged as a treatment strategy which stimulates
the human immune system to kill tumor cells. Tumor immunotherapy is based on immune …

Triple-negative breast cancer (TNBC) is a subtype of human breast cancer with one of the
worst prognoses, with no targeted therapeutic strategies currently available. Regulated cell …

Heterogeneity of triple-negative breast cancer is well known at clinical, histopathological,
and molecular levels. Genomic instability and greater mutation rates, which may result in the …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

Enhancing natural killer (NK) cell-based innate immunity has become a promising strategy
for immunotherapy against hard-to-cure solid cancers. Monoclonal antibody (mAb) therapy …

Simple Summary A bottleneck in oncology is the translation of results from preclinical
models to the clinics. The rate of anticancer drugs that are effective in preclinical studies but …

The successful treatment of patients affected by B-cell malignancies with Chimeric Antigen
Receptor (CAR)-T cells represented a breakthrough in the field of adoptive cell therapy …

Simple Summary This review is intended to provide an overview on the history and recent
advances of T cell and natural killer (NK) cell-based immunotherapy. While the thymus was …

Nanotechnology has been widely applied in tumor imaging, diagnostic and therapy. Beside
the prefabricated nanomaterials, constructing nanostructures in living cells through self …

Triple-negative breast cancer (TNBC) accounts for about 10-20% of all breast cancer cases
and is associated with an unfavorable prognosis. Until recently, treatment options for TNBC …